Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial

Launched by SECOND AFFILIATED HOSPITAL OF NANCHANG UNIVERSITY · Apr 28, 2022

Keywords

ClinConnect Summary

Vernal keratoconjunctivitis (VKC) is an allergic disease that severely affects the eyesight of adolescents. Vernal keratoconjunctivitis (VKC) usually occurs in temperate regions such as the Mediterranean region, the Middle East, Africa, Central America, and the Indian subcontinent. In the EU an estimated 3.2 per 10,000 inhabitants (0.03%). It occurs repeatedly and mainly involves type I and type IV hypersensitivity. long-term standardized treatment is necessary. Therefore, this research aims to compare the readily available cyclosporine 0.05% eye drops and Loteprednol Etabonate 0.5% and Tob...

Gender

ALL

Eligibility criteria

• • Inclusion criteria
• • patients had a noticeable seasonal, and recurrent Itching, Discomfort(burning, stinging, and foreign body sensation), Photophobia and tears, Viscous discharge;
• • Slit-lamp microscopy showed Conjunctival Hyperemia, Tarsal papillary, Limbal hypertrophy, Horner-Trantas dots, Keratitis in some patients;
• • No other medication history in recent 2 weeks;
• • Patients have high compliance and are willing to take drugs on time and return to the clinic in time
• Exclusion criteria:
• • with other related immune diseases or other drug use history in recent 2 weeks;
• • Patients with evident and severe organic diseases or mental diseases;
• • Low compliance, unable to take drugs on time or fail to return to the clinic on time.